SteadyMed Announces FDA Agreed Pathway to Trevyent NDA Resubmission Post author:Sam Post published:December 7, 2017 Post category:BioPharma No clinical trials are required for the NDA resubmission. Source: BioSpace You Might Also Like Nestle's Galderma Laboratories to Slash Up to 450 Jobs at R&D Center September 20, 2017 Why a Celgene-Juno Marriage Makes Perfect Sense January 17, 2018 Phoenix Molecular Designs Appoints Leading Oncology Expert As Chief Scientific Officer July 16, 2017
